Efficacy and safety of osimertinib in a Japanese compassionate use program.

MLA

Fujiwara, Yutaka, et al. “Efficacy and Safety of Osimertinib in a Japanese Compassionate Use Program.” Japanese Journal of Clinical Oncology, vol. 47, no. 7, July 2017, pp. 625–29. EBSCOhost, https://doi.org/10.1093/jjco/hyx050.

APA

Fujiwara, Y., Goto, Y., Kanda, S., Horinouchi, H., Yamamoto, N., Sakiyama, N., Ando Makihara, R., & Ohe, Y. (2017). Efficacy and safety of osimertinib in a Japanese compassionate use program. Japanese Journal of Clinical Oncology, 47(7), 625–629. https://doi.org/10.1093/jjco/hyx050

Chicago

Fujiwara, Yutaka, Yasushi Goto, Shintaro Kanda, Hidehito Horinouchi, Noboru Yamamoto, Naomi Sakiyama, Reiko Ando Makihara, and Yuichiro Ohe. 2017. “Efficacy and Safety of Osimertinib in a Japanese Compassionate Use Program.” Japanese Journal of Clinical Oncology 47 (7): 625–29. doi:10.1093/jjco/hyx050.